Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C.
| Ano de defesa: | 2024 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | |
| Tipo de documento: | Dissertação |
| Tipo de acesso: | Acesso aberto |
| Idioma: | por |
| Instituição de defesa: |
Universidade Federal de Minas Gerais
|
| Programa de Pós-Graduação: |
Não Informado pela instituição
|
| Departamento: |
Não Informado pela instituição
|
| País: |
Não Informado pela instituição
|
| Link de acesso: | https://hdl.handle.net/1843/77604 |
Resumo: | Hepatitis C is caused by a virus from the Flaviviridae family, genus Hepacivirus, called Hepatitis C Virus (HCV). In most cases, the infection has no symptoms in the acute phase but becomes chronic in 75 to 85% of the affected ones. It is estimated that 71 million people live with chronic hepatitis C worldwide, leading to liver fibrosis, cirrhosis, hepatocarcinoma, and various other associated extra-hepatic conditions. The initial diagnosis of HCV infection is usually made by detecting antibodies in serum and plasma samples. However, the use of dried blood samples impregnated in filter paper (DBS) and point-of-care methodologies are alternatives for screening individuals at high risk of infection in places with poor laboratory infrastructure. This study aimed to standardize and validate an enzyme-linked immunosorbent assay (ELISA) for the detection of anti-HCV antibodies in serum, plasma, and DBS samples and to standardize an immunochromatographic test for the detection of anti-HCV antibodies in serum, plasma, and blood samples. For ELISA, 237 serum and plasma samples and 185 DBS samples were used. The assay developed demonstrated a sensitivity and specificity of >99.99%. In the comparative analytical sensitivity, the DBS samples obtained a kappa index of 0.41, with regular agreement. The repeatability, reproducibility, and inter-assay analyses showed results with a coefficient of variation of <20%. For the immunochromatographic test, 90 serum samples were used, showing a sensitivity and specificity of >99.99%. In comparative analytical sensitivity, the rapid test with serum samples obtained a kappa of 1.0, with perfect agreement, while the use of blood samples obtained a kappa of 0.61, representing good agreement. These results support the good functioning of the assays developed for the serological diagnosis of HCV infection both in serum/plasma samples and in DBS and blood samples, in the ELISA and rapid test methodologies. |
| id |
UFMG_52ec9e7bb4a4eaa84edc25e491536e26 |
|---|---|
| oai_identifier_str |
oai:repositorio.ufmg.br:1843/77604 |
| network_acronym_str |
UFMG |
| network_name_str |
Repositório Institucional da UFMG |
| repository_id_str |
|
| spelling |
2024-10-23T18:07:29Z2025-09-09T00:47:30Z2024-10-23T18:07:29Z2024-06-13https://hdl.handle.net/1843/77604Hepatitis C is caused by a virus from the Flaviviridae family, genus Hepacivirus, called Hepatitis C Virus (HCV). In most cases, the infection has no symptoms in the acute phase but becomes chronic in 75 to 85% of the affected ones. It is estimated that 71 million people live with chronic hepatitis C worldwide, leading to liver fibrosis, cirrhosis, hepatocarcinoma, and various other associated extra-hepatic conditions. The initial diagnosis of HCV infection is usually made by detecting antibodies in serum and plasma samples. However, the use of dried blood samples impregnated in filter paper (DBS) and point-of-care methodologies are alternatives for screening individuals at high risk of infection in places with poor laboratory infrastructure. This study aimed to standardize and validate an enzyme-linked immunosorbent assay (ELISA) for the detection of anti-HCV antibodies in serum, plasma, and DBS samples and to standardize an immunochromatographic test for the detection of anti-HCV antibodies in serum, plasma, and blood samples. For ELISA, 237 serum and plasma samples and 185 DBS samples were used. The assay developed demonstrated a sensitivity and specificity of >99.99%. In the comparative analytical sensitivity, the DBS samples obtained a kappa index of 0.41, with regular agreement. The repeatability, reproducibility, and inter-assay analyses showed results with a coefficient of variation of <20%. For the immunochromatographic test, 90 serum samples were used, showing a sensitivity and specificity of >99.99%. In comparative analytical sensitivity, the rapid test with serum samples obtained a kappa of 1.0, with perfect agreement, while the use of blood samples obtained a kappa of 0.61, representing good agreement. These results support the good functioning of the assays developed for the serological diagnosis of HCV infection both in serum/plasma samples and in DBS and blood samples, in the ELISA and rapid test methodologies.porUniversidade Federal de Minas GeraisDiagnósticoHepatite CELISADBSTeste rápidoValidaçãoPadronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C.Standardization and validation of serological assays for the diagnosis of Hepatitis C.info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisLaís Dias Ribeiroinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGhttp://lattes.cnpq.br/9709953932619987Jenner Karlisson Pimenta dos Reishttp://lattes.cnpq.br/3641356939660511Luiz Guilherme Dias HeneideBruno Eduardo Fernandes MotaVicente de Paulo Coelho Peixoto de ToledoA Hepatite C é causada por um vírus da família Flaviviridae, gênero Hepacivirus, denominado HCV. Na maioria dos casos, a infecção não possui sintomatologia na fase aguda, mas se torna crônica em 75 a 85% dos acometidos. Estima-se que 71 milhões de pessoas convivem com hepatite C crônica em todo o mundo, levando a quadros de fibrose hepática, cirrose, hepatocarcinoma e diversos outros quadros extra-hepáticos associados. O diagnóstico inicial da infecção pelo HCV é feito geralmente pela detecção anticorpos em amostras de soro e plasma. Entretanto, a utilização de amostras de sangue impregnado em papel de filtro (DBS) e metodologias point-of-care são alternativas para a triagem de indivíduos com alto risco de infecção em locais com baixa infraestrutura laboratorial. Este trabalho teve como objetivos a padronização e a validação de um imunoensaio enzimático (ELISA) para a detecção de anticorpos anti-HCV em amostras de soro, plasma e DBS e a padronização de um teste imunocromatográfico para a detecção de anticorpos anti-HCV em amostras de soro, plasma e sangue. Um total de 237 amostras de soro e plasma e 185 amostras de DBS foram utilizadas no estudo do ELISA. O ensaio desenvolvido demostrou uma sensibilidade e especificidade >99,99%. Na sensibilidade analítica comparada, as amostras de DBS obtiveram um índice kappa de 0,41, com concordância regular. As análises de repetibilidade, reprodutibilidade e interensaio apresentaram resultados com coeficiente de variação <20%. Para o ensaio imunocromatográfico, um total de 90 amostras de soro foram utilizadas, demonstrando uma sensibilidade e especificidade >99,99%. Na sensibilidade analítica comparada, o teste rápido com amostras de soro obteve um kappa de 1,0, com concordância perfeita, enquanto a utilização de amostras de sangue obteve um kappa de 0,61, representando uma boa concordância. Esses resultados respaldam o bom funcionamento dos ensaios desenvolvidos para o diagnóstico sorológico da infecção pelo HCV tanto em amostras de soro/plasma quanto em amostras de DBS e sangue, nas metodologias de ELISA e teste rápido.BrasilFARMACIA - FACULDADE DE FARMACIAPrograma de Pós-Graduação em Análises Clínicas e ToxicológicasUFMGORIGINALDissertação de Mestrado - Laís Dias Ribeiro - Versão Final.pdfapplication/pdf2250690https://repositorio.ufmg.br//bitstreams/1cf40017-98c8-4c83-a5ea-6967cc284c45/downloadc11856d15ba28675504e7e6e67b0bef6MD51trueAnonymousREADLICENSElicense.txttext/plain2118https://repositorio.ufmg.br//bitstreams/e7d06e80-b5e9-4e57-8ba3-2485b4461b36/downloadcda590c95a0b51b4d15f60c9642ca272MD52falseAnonymousREAD1843/776042025-09-08 21:47:30.353open.accessoai:repositorio.ufmg.br:1843/77604https://repositorio.ufmg.br/Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2025-09-09T00:47:30Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)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 |
| dc.title.none.fl_str_mv |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| dc.title.alternative.none.fl_str_mv |
Standardization and validation of serological assays for the diagnosis of Hepatitis C. |
| title |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| spellingShingle |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. Laís Dias Ribeiro Diagnóstico Hepatite C ELISA DBS Teste rápido Validação |
| title_short |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| title_full |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| title_fullStr |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| title_full_unstemmed |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| title_sort |
Padronização e validação de ensaios sorológicos para o diagnóstico da Hepatite C. |
| author |
Laís Dias Ribeiro |
| author_facet |
Laís Dias Ribeiro |
| author_role |
author |
| dc.contributor.author.fl_str_mv |
Laís Dias Ribeiro |
| dc.subject.other.none.fl_str_mv |
Diagnóstico Hepatite C ELISA DBS Teste rápido Validação |
| topic |
Diagnóstico Hepatite C ELISA DBS Teste rápido Validação |
| description |
Hepatitis C is caused by a virus from the Flaviviridae family, genus Hepacivirus, called Hepatitis C Virus (HCV). In most cases, the infection has no symptoms in the acute phase but becomes chronic in 75 to 85% of the affected ones. It is estimated that 71 million people live with chronic hepatitis C worldwide, leading to liver fibrosis, cirrhosis, hepatocarcinoma, and various other associated extra-hepatic conditions. The initial diagnosis of HCV infection is usually made by detecting antibodies in serum and plasma samples. However, the use of dried blood samples impregnated in filter paper (DBS) and point-of-care methodologies are alternatives for screening individuals at high risk of infection in places with poor laboratory infrastructure. This study aimed to standardize and validate an enzyme-linked immunosorbent assay (ELISA) for the detection of anti-HCV antibodies in serum, plasma, and DBS samples and to standardize an immunochromatographic test for the detection of anti-HCV antibodies in serum, plasma, and blood samples. For ELISA, 237 serum and plasma samples and 185 DBS samples were used. The assay developed demonstrated a sensitivity and specificity of >99.99%. In the comparative analytical sensitivity, the DBS samples obtained a kappa index of 0.41, with regular agreement. The repeatability, reproducibility, and inter-assay analyses showed results with a coefficient of variation of <20%. For the immunochromatographic test, 90 serum samples were used, showing a sensitivity and specificity of >99.99%. In comparative analytical sensitivity, the rapid test with serum samples obtained a kappa of 1.0, with perfect agreement, while the use of blood samples obtained a kappa of 0.61, representing good agreement. These results support the good functioning of the assays developed for the serological diagnosis of HCV infection both in serum/plasma samples and in DBS and blood samples, in the ELISA and rapid test methodologies. |
| publishDate |
2024 |
| dc.date.accessioned.fl_str_mv |
2024-10-23T18:07:29Z 2025-09-09T00:47:30Z |
| dc.date.available.fl_str_mv |
2024-10-23T18:07:29Z |
| dc.date.issued.fl_str_mv |
2024-06-13 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
| format |
masterThesis |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://hdl.handle.net/1843/77604 |
| url |
https://hdl.handle.net/1843/77604 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
| publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
| instname_str |
Universidade Federal de Minas Gerais (UFMG) |
| instacron_str |
UFMG |
| institution |
UFMG |
| reponame_str |
Repositório Institucional da UFMG |
| collection |
Repositório Institucional da UFMG |
| bitstream.url.fl_str_mv |
https://repositorio.ufmg.br//bitstreams/1cf40017-98c8-4c83-a5ea-6967cc284c45/download https://repositorio.ufmg.br//bitstreams/e7d06e80-b5e9-4e57-8ba3-2485b4461b36/download |
| bitstream.checksum.fl_str_mv |
c11856d15ba28675504e7e6e67b0bef6 cda590c95a0b51b4d15f60c9642ca272 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
| repository.mail.fl_str_mv |
repositorio@ufmg.br |
| _version_ |
1862106055312408576 |